Regulators add warning to Bextra, allow new indication

The FDA has provided a new warning and a new indication for Celebrex, the only remaining Cox-2 inhibitor left on the market. The new warning will highlight the added risks of heart attacks and other cardiovascular conditions. Celebrex was also approved for use against ankylosing spondylitis, a form of spinal arthritis that affects about 400,000 Americans.

Sales of Celebrex have plunged 45 percent in the second quarter of 2005, with total sales of $401 million. Pfizer's other Cox-2 inhibitor, Bextra, was pulled from the market after the FDA asked the company to withdraw the anti-inflammatory after a review of its cardiovascular risks.

- read this report from MarketWatch for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.